Clinical Trial Update: A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) [Phase 3]

View source ↗

Summary

A Phase 3 study compares sacituzumab Tirumotecan (MK-2870) in combination with pembrolizumab (MK-3475) versus pembrolizumab alone in endometrial cancer. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Cancer | Phase 3 | Status: RECRUITING